These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 14594437)

  • 1. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.
    Martin SC; Gagnon DD; Zhang L; Bokemeyer C; Van Marwijk Kooy M; van Hout B
    Pharmacoeconomics; 2003; 21(16):1153-69. PubMed ID: 14594437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
    Wilson J; Yao GL; Raftery J; Bohlius J; Brunskill S; Sandercock J; Bayliss S; Moss P; Stanworth S; Hyde C
    Health Technol Assess; 2007 Apr; 11(13):1-202, iii-iv. PubMed ID: 17408534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of epoetin alfa in a retrospective non-stratified subgroup analysis of a breast cancer cohort receiving non-platinum chemotherapy.
    Bajetta E; Vercammen E; Reinhardt U; Janmohamed R; da Costa RM; Matulonis U; Guastalla JP;
    Tumori; 2004; 90(5):449-57. PubMed ID: 15656327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
    Littlewood TJ; Bajetta E; Nortier JW; Vercammen E; Rapoport B;
    J Clin Oncol; 2001 Jun; 19(11):2865-74. PubMed ID: 11387359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost of managing anemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy.
    Meadowcroft AM; Gilbert CJ; Maravich-May D; Hayward SL
    Am J Health Syst Pharm; 1998 Sep; 55(18):1898-902. PubMed ID: 9784769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis.
    Ortega A; Dranitsaris G; Puodziunas AL
    Cancer; 1998 Dec; 83(12):2588-96. PubMed ID: 9874467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.
    Hudis CA; Vogel CL; Gralow JR; Williams D;
    Clin Breast Cancer; 2005 Jun; 6(2):132-42. PubMed ID: 16001991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
    Littlewood TJ; Nortier J; Rapoport B; Pawlicki M; de Wasch G; Vercammen E; Schuette W; Wils J; Freund M;
    Hematol Oncol; 2003 Dec; 21(4):169-80. PubMed ID: 14735555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy.
    Crawford J; Robert F; Perry MC; Belani C; Williams D;
    J Thorac Oncol; 2007 Mar; 2(3):210-20. PubMed ID: 17410044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy.
    O'Shaughnessy JA; Vukelja SJ; Holmes FA; Savin M; Jones M; Royall D; George M; Von Hoff D
    Clin Breast Cancer; 2005 Feb; 5(6):439-46. PubMed ID: 15748464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.
    Gabrilove JL; Cleeland CS; Livingston RB; Sarokhan B; Winer E; Einhorn LH
    J Clin Oncol; 2001 Jun; 19(11):2875-82. PubMed ID: 11387360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ; Jacobson DR
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy.
    Fallowfield L; Gagnon D; Zagari M; Cella D; Bresnahan B; Littlewood TJ; McNulty P; Gorzegno G; Freund M;
    Br J Cancer; 2002 Dec; 87(12):1341-53. PubMed ID: 12454760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.
    Chang J; Couture F; Young S; McWatters KL; Lau CY
    J Clin Oncol; 2005 Apr; 23(12):2597-605. PubMed ID: 15452188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer.
    Fagnoni P; Limat S; Chaigneau L; Guardiola E; Briaud S; Schmitt B; Merrouche Y; Pivot X; Woronoff-Lemsi MC
    Support Care Cancer; 2006 Oct; 14(10):1030-7. PubMed ID: 16802128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.
    Quirt I; Robeson C; Lau CY; Kovacs M; Burdette-Radoux S; Dolan S; Tang SC; McKenzie M; Couture F;
    J Clin Oncol; 2001 Nov; 19(21):4126-34. PubMed ID: 11689580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials.
    Glaspy J; Degos L; Dicato M; Demetri GD
    Oncologist; 2002; 7(2):126-35. PubMed ID: 11961196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.